Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jun;7(6):505.
doi: 10.1016/S2468-1253(22)00122-4.

Neoadjuvant immunotherapy for resectable hepatocellular carcinoma - Authors' reply

Thomas U Marron  1 , Myron E Schwartz  2 , Elizabeth Miller  3 , Pradeep Thanigaimani  3 , Israel Lowy  3 , Gavin Thurston  3 , Miriam Merad  4
Affiliations
Comment

Neoadjuvant immunotherapy for resectable hepatocellular carcinoma - Authors' reply

Thomas U Marron et al. Lancet Gastroenterol Hepatol. 2022 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

TUM has received research funding from Boehringer Ingelheim, Bristol Myers Squibb, Merck, and Regeneron Pharmaceuticals, and has served on advisory boards or data safety monitoring boards, or both, of AstraZeneca, Atara, Boehringer Ingelheim, Celldex, Chimeric Therapeutics, Genentech, Regeneron Pharmaceuticals, Riboscience, and the Rockefeller University. EM, IL, and GT are employees and shareholders of Regeneron Pharmaceuticals. PT reports stock ownership in Mannkind and is an employee and shareholder of Regeneron Pharmaceuticals.MM reports consulting roles with Asher Bio, Celsius Therapeutics, Compugen, Dren Bio, Genenta, Innate Pharma, Morphic Therapeutic, Myeloid Therapeutics, and Nirogy Therapeutics. MM also receives research funding from Boehringer Ingelheim, Genentech, Regeneron Pharmaceuticals, and Takeda; honoraria from Amgen and GSK; and reports ownership interest less than 5% in Asher Bio, Celsius Therapeutics, Compugen, Dren Bio, Genenta, Morphic Therapeutic, Myeloid Therapeutics, and Nirogy Therapeutics. MES declares no competing interests.

Comment on

  • Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.
    Marron TU, Fiel MI, Hamon P, Fiaschi N, Kim E, Ward SC, Zhao Z, Kim J, Kennedy P, Gunasekaran G, Tabrizian P, Doroshow D, Legg M, Hammad A, Magen A, Kamphorst AO, Shareef M, Gupta NT, Deering R, Wang W, Wang F, Thanigaimani P, Mani J, Troncoso L, Tabachnikova A, Chang C, Akturk G, Buckup M, Hamel S, Ioannou G, Hennequin C, Jamal H, Brown H, Bonaccorso A, Labow D, Sarpel U, Rosenbloom T, Sung MW, Kou B, Li S, Jankovic V, James N, Hamon SC, Cheung HK, Sims JS, Miller E, Bhardwaj N, Thurston G, Lowy I, Gnjatic S, Taouli B, Schwartz ME, Merad M. Marron TU, et al. Lancet Gastroenterol Hepatol. 2022 Mar;7(3):219-229. doi: 10.1016/S2468-1253(21)00385-X. Epub 2022 Jan 20. Lancet Gastroenterol Hepatol. 2022. PMID: 35065058 Free PMC article. Clinical Trial.
  • Neoadjuvant immunotherapy for resectable hepatocellular carcinoma.
    Wei F. Wei F. Lancet Gastroenterol Hepatol. 2022 Jun;7(6):504. doi: 10.1016/S2468-1253(22)00083-8. Lancet Gastroenterol Hepatol. 2022. PMID: 35550049 No abstract available.

Substances

LinkOut - more resources